ZZZihang Zhou

Zihang Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zihang Zhou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Chuanxi Tang

    Xuzhou Key Laboratory of Neurobiology, Department of Neurobiology, Xuzhou Medical University, Xuzhou 221004, China

    1 shared publication
  • Chunyan Mu

    Department of Psychiatry and Psychology, Xuzhou Medical University Affiliated Xuzhou Oriental Hospital, 221000 Xuzhou, Jiangsu, China

    1 shared publication
  • Heng Gu

    Department of Neurobiology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu Province, China

    1 shared publication
  • Ke Xue

    Department of Neurobiology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu Province, China

    1 shared publication
  • Peng Xie

    Department of Neurosurgery, The Second People’s Hospital of Huai’an and The Affiliated Huai’an Hospital of Xuzhou Medical University, 223001 Huai’an, Jiangsu, China

    1 shared publication
  • Qiuhong Ji

    Affiliated Hospital of Nantong university, Nantong, China

    1 shared publication

Latest Publications

  • Open Access

    Mechanistic Study on HSP90B1 Regulation of ClC-7 Ubiquitination to Restore Lysosomal Function in the Protection Proffered by DGMI Against Fluoride-Induced Cognitive Dysfunction

    by Rui Chen, Peng Xie, Xinrui Fan, Zihang Zhou, Chunyan Mu, Qiuhong Ji

    Background: Fluorosis can induce cognitive dysfunction. The cognitive impairment caused by fluorosis is closely related to endoplasmic reticulum stress (ERS) and abnormal lysosomal acidification. However, the specific molecular mechanism is not known, and effective intervention strategies are lacking. Diterpene ginkgolides meglumine injection (DGMI) is used clinically as a neuroprotective agent, but whether it can inhibit ERS, regulate lysosomal acidification, and ameliorate fluorosis-induced cognitive dysfunction merits investigation. Methods: We used the Morris water maze to detect the cognitive function of mice, evaluated the neuronal survival by Nissl staining, assessed the apoptotic status in hippocampal neurons of mice by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining, and observed the degree of synaptic plasticity damage using Golgi staining and transmission electron microscopy. In cell experiments, we used the OG488 acidophilic fluorescent probe to detect lysosomal acidity; detected the co-localization of HSP90B1 with the ER and the co-localization of the chloride channel, voltage-sensitive 7 (ClC-7) with lysosomes using immunofluorescence technology; employed co-immunoprecipitation to detect the binding of HSP90B1, ClC-7, and membrane-associated RING-CH protein 1 (MARCHF1) as well as the ubiquitination degradation level of ClC-7; used western blotting to measure expression of ERS-related proteins (PERK, IRE1α, ATF6), glycogen synthase kinase 3β, and mammalian target of rapamycin signals. Results: DGMI significantly improved cognitive dysfunction in C57BL/6 mice with fluorosis, inhibited hippocampal neuronal apoptosis, and improved synaptic plasticity damage. In cell experiments, the detection results of apoptosis and percent survival were consistent with those of animal experiments in that DGMI could alleviate sodium fluoride-induced ERS and lysosomal-acidification disorders in HT22 cells. DGMI downregulates the expression of the ER chaperone HSP90B1, weakens its interaction with ClC-7, thereby inhibiting the MARCHF1 E3 ligase-mediated ubiquitination and degradation of ClC-7, ultimately alleviating lysosomal acidification disorders and improving cognitive function. Conclusions: DGMI may exert cognitive protective effects against fluorosis-induced cognitive impairment by regulating lysosomal acidification through the HSP90B1–ClC-7 axis, which also alleviates ERS, apoptosis, and other related neuropathologic injuries.

  • Open Access

    Dopamine in the prefrontal cortex plays multiple roles in the executive function of patients with Parkinson's disease

    by Zihang Zhou, Yalong Yan, Heng Gu, Ruiao Sun, Zihan Liao, Ke Xue, Chuanxi Tang

    Parkinson's disease can affect not only motor functions but also cognitive abilities, leading to cognitive impairment. One common issue in Parkinson's disease with cognitive dysfunction is the difficulty in executive functioning. Executive functions help us plan, organize, and control our actions based on our goals. The brain area responsible for executive functions is called the prefrontal cortex. It acts as the command center for the brain, especially when it comes to regulating executive functions. The role of the prefrontal cortex in cognitive processes is influenced by a chemical messenger called dopamine. However, little is known about how dopamine affects the cognitive functions of patients with Parkinson's disease. In this article, the authors review the latest research on this topic. They start by looking at how the dopaminergic system, is altered in Parkinson's disease with executive dysfunction. Then, they explore how these changes in dopamine impact the synaptic structure, electrical activity, and connection components of the prefrontal cortex. The authors also summarize the relationship between Parkinson's disease and dopamine-related cognitive issues. This information may offer valuable insights and directions for further research and improvement in the clinical treatment of cognitive impairment in Parkinson's disease.